Entrada Therapeutics Files Proxy Statement
Ticker: TRDA · Form: DEFA14A · Filed: Jun 3, 2025 · CIK: 1689375
| Field | Detail |
|---|---|
| Company | Entrada Therapeutics, Inc. (TRDA) |
| Form Type | DEFA14A |
| Filed Date | Jun 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, sec
Related Tickers: TRDA
TL;DR
Entrada Therapeutics (TRDA) filed its proxy statement on 6/3/25. Standard shareholder vote stuff.
AI Summary
Entrada Therapeutics, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 3, 2025. This filing is related to the company's proxy materials, likely concerning upcoming shareholder meetings and voting matters. The company, formerly known as CycloPorters, Inc., is based in Boston, MA, and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing is a standard regulatory requirement for public companies to communicate with shareholders about important matters requiring a vote, such as board elections or corporate actions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new financial information or strategic decisions that would inherently increase risk.
Key Players & Entities
- Entrada Therapeutics, Inc. (company) — Registrant
- CycloPorters, Inc. (company) — Former company name
- 0001104659-25-055720 (filing_id) — Accession Number
- 20250603 (date) — Filing Date
FAQ
What type of filing is this DEFA14A for Entrada Therapeutics, Inc.?
This is a Definitive Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.
When was this filing submitted to the SEC?
The filing was submitted on June 3, 2025.
What is the Central Index Key (CIK) for Entrada Therapeutics, Inc.?
The CIK for Entrada Therapeutics, Inc. is 0001689375.
What was Entrada Therapeutics, Inc. formerly known as?
Entrada Therapeutics, Inc. was formerly known as CycloPorters, Inc.
Where is Entrada Therapeutics, Inc. located?
Entrada Therapeutics, Inc. is located in Boston, MA, with a business address at One Design Center Place, Suite 17-500, Boston, MA 02210.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 3, 2025 regarding Entrada Therapeutics, Inc. (TRDA).